Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

M. A. Socinski, R. M. Jotte, F. Cappuzzo, F. Orlandi, D. Stroyakovskiy, N. Nogami, D. Rodriguez-Abreu, D. Moro-Sibilot, C. A. Thomas, F. Barlesi, G. Finley, C. Kelsch, A. Lee, S. Coleman, Y. Deng, Y. Shen, M. Kowanetz, A. Lopez-Chavez, A. Sandler, M. Reck*IMpower150 Study Grp, Anne-Marie Dingemans

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)2288-2301
Number of pages14
JournalNew England Journal of Medicine
Volume378
Issue number24
DOIs
Publication statusPublished - 14 Jun 2018

Keywords

  • PHASE-III TRIAL
  • OPEN-LABEL
  • CANCER
  • BEVACIZUMAB
  • THERAPY
  • DOCETAXEL
  • ANTIBODY
  • CELLS
  • CHEMOTHERAPY
  • MULTICENTER

Cite this

Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodriguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., Finley, G., Kelsch, C., Lee, A., Coleman, S., Deng, Y., Shen, Y., Kowanetz, M., Lopez-Chavez, A., Sandler, A., ... Dingemans, A-M. (2018). Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. New England Journal of Medicine, 378(24), 2288-2301. https://doi.org/10.1056/NEJMoa1716948